Neal Shore, M.D., FACS, Medical Director for START Carolina Research Center, and lead investigator for the CREST trial.
- Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) regimen compared to SOC alone
- Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in more than 30 years
- Results have been shared with global health authorities to support potential regulatory filings
Leave a Reply
Want to join the discussion?Feel free to contribute!